Evidence map›Paper›PMID 32992508›Full record

ArticleMolecules (Basel, Switzerland)2020

Protective Effects of Eicosapentaenoic Acid Plus Hydroxytyrosol Supplementation Against White Adipose Tissue Abnormalities in Mice Fed a High-Fat Diet.

Paola Illesca, Rodrigo Valenzuela, Alejandra Espinosa, Francisca Echeverría, Sandra Soto-Alarcon, Cristian Campos, Alicia Rodriguez, Romina Vargas, Thea Magrone, Luis A Videla

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 3 countries.

Paola IllescaLaboratory of Studies of Metabolic Diseases Related to Nutrition. Faculty of Biochemistry. University of Litoral, Santa Fe 3000, Argentina.ORCID 0000-0002-8491-2458
Rodrigo ValenzuelaNutrition Department, Faculty of Medicine, University of Chile, Santiago 8380000, Chile.ORCID 0000-0001-9298-6142
Alejandra EspinosaMedical Technology Department, Faculty of Medicine, University of Chile, Santiago 8380000, Chile.
Francisca EcheverríaNutrition Department, Faculty of Medicine, University of Chile, Santiago 8380000, Chile.ORCID 0000-0002-9661-0377
Sandra Soto-AlarconNutrition Department, Faculty of Medicine, University of Chile, Santiago 8380000, Chile.
Cristian CamposMedical Technology Department, Faculty of Medicine, University of Chile, Santiago 8380000, Chile.
Alicia RodriguezDepartment of Food Science and Chemical Technology, Faculty of Chemical and Pharmaceutical Sciences, University of Chile, Santiago 8380494, Chile.ORCID 0000-0003-2750-2468
Romina VargasMolecular and Clinical Pharmacology Program, Institute of Biomedical Science, Faculty of Medicine, University of Chile, Santiago 8380000, Chile.
Thea MagroneDepartment of Basic Medical Sciences, Neuroscience and Sensory Organs, University of Bari, 70124 Bari, Italy.
Luis A VidelaMolecular and Clinical Pharmacology Program, Institute of Biomedical Science, Faculty of Medicine, University of Chile, Santiago 8380000, Chile.ORCID 0000-0002-1788-6667
University of Chile · CLUniversidad Nacional del Litoral · ARUniversity of Bari Aldo Moro · IT

Funding

Fondo Nacional de Desarrollo Científico y Tecnológico 11140174Fondo Nacional de Desarrollo Científico y Tecnológico 1181774
6 · The paper itself

Abstract

objectiveObesity induced by high-fat diet (HFD) elicits white adipose tissue dysfunction. In this study, we have hypothesized that the metabolic modulator eicosapentaenoic acid (EPA) combined with the antioxidant hydroxytyrosol (HT) attenuates HFD-induced white adipose tissue (WAT) alterations.

methodsC57BL/6J mice were administered with a HFD (60% fat, 20% protein, 20% carbohydrates) or control diet (CD; 10% fat, 20% protein, 70% carbohydrates), with or without EPA (50 mg/kg/day), HT (5 mg/kg/day), or both for 12 weeks. Determinations in WAT include morphological parameters, EPA and docosahexaenoic acid content in phospholipids (gas chromatography), lipogenesis, oxidative stress (OS) and inflammation markers, and gene expression and activities of transcription factors, such as sterol regulatory element-binding protein-1c (SREBP-1c), peroxisome proliferator-activated receptor-gamma (PPAR-γ), nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) (p65 subunit) and nuclear factor erythroid 2-related factor 2 (Nrf2) (quantitative polymerase chain reaction and enzyme linked immunosorbent assay).

resultsHFD led to WAT hypertrophy in relation to PPAR-γ downregulation. WAT metabolic dysfunction was characterized by upregulation of lipogenic SREBP-1c system, mitochondrial energy metabolism depression, loss of the antioxidant Nrf2 signaling with OS enhancement, n-3 long-chain polyunsaturated fatty acids depletion and activation of the pro-inflammatory NF-κB system. EPA and HT co-supplementation diminished HFD-dependent effects additively, reaching values close or similar to controls.

conclusionData presented strengthen the importance of combined protocols such as EPA plus HT to attenuate metabolic-inflammatory states triggered by obesity.

Indexed as

ObesityAdipose Tissue, WhiteAnimalsDiet, High-FatEicosapentaenoic AcidGene Expression RegulationMaleMicePhenylethyl Alcohol3,4-dihydroxyphenylethanolEicosapentaenoic AcidPhenylethyl Alcoholadipocyte hypertrophyeicosapentaenoic acidhigh-fat diethydroxytyrosolmetabolic dysfunctionwhite adipose tissue

Identifiers

PMID32992508
PMCPMC7582637
OpenAlexW3087853031

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.